1. Home
  2. WEST vs GERN Comparison

WEST vs GERN Comparison

Compare WEST & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westrock Coffee Company

WEST

Westrock Coffee Company

HOLD

Current Price

$7.57

Market Cap

747.3M

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.43

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEST
GERN
Founded
2009
1990
Country
United States
United States
Employees
1393
258
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
747.3M
808.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WEST
GERN
Price
$7.57
$1.43
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
$7.00
$2.17
AVG Volume (30 Days)
683.8K
10.3M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.27
$26.91
Revenue Next Year
$10.66
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.59
$1.04
52 Week High
$10.19
$2.01

Technical Indicators

Market Signals
Indicator
WEST
GERN
Relative Strength Index (RSI) 47.26 53.59
Support Level $7.26 $1.39
Resistance Level $8.76 $1.46
Average True Range (ATR) 0.44 0.08
MACD 0.03 -0.01
Stochastic Oscillator 67.20 27.78

Price Performance

Historical Comparison
WEST
GERN

About WEST Westrock Coffee Company

Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: